CASE MATCH CONTROL ANALYSIS OF PROPEL REVEALS A SURVIVAL ADVANTAGE FOR PATIENTS WITH RELAPSED PTCL RECEIVING PRALATREXATE: A NOVEL APPROACH TO BENCHMARK DRUGS IN RARE DISEASES
Sign Up to like & getrecommendations! Published in 2017 at "Hematological Oncology"
DOI: 10.1002/hon.2438_113
Abstract: and two had treatment tolerance requiring a change in therapy. In this group (n = 24), the median OS after BV failure was only 3 months, and 2‐year OS was 30%. Of 6 long‐term (>1… read more here.
Keywords: reveals survival; analysis propel; case match; propel reveals ... See more keywords